BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day

Reuters12-11

Dec 11 (Reuters) - Roivant Sciences Ltd ROIV.O:

ROIVANT HIGHLIGHTS CONTINUED PIPELINE PROGRESS AND OUTLOOK FOR COMPANY’S NEXT PHASE OF GROWTH AT 2025 INVESTOR DAY
ROIVANT SCIENCES LTD - BREPOCITINIB NDA FILING EXPECTED EARLY 2026, LAUNCH IN 2027
ROIVANT SCIENCES LTD - BREPOCITINIB PHASE 3 TRIAL IN NIU FULLY ENROLLED, DATA EXPECTED H2 2026
ROIVANT SCIENCES LTD - IMVT-1402 TRIAL IN D2T RA TOPLINE DATA EXPECTED 2026

Source text: ID:nGNX3LqfMN

Further company coverage: ROIV.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590513028?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590513028","market":"fut","top_or_hot":-1,"title":"BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day</title></head><body><p><span>Dec 11 (Reuters)</span><span> - </span>Roivant Sciences Ltd <span>ROIV.O</span>:</p><ul><li><p>ROIVANT HIGHLIGHTS CONTINUED PIPELINE PROGRESS AND OUTLOOK FOR COMPANY’S NEXT PHASE OF GROWTH AT 2025 INVESTOR DAY</p></li><li><p>ROIVANT SCIENCES LTD - BREPOCITINIB NDA FILING EXPECTED EARLY 2026, LAUNCH IN 2027</p></li><li><p>ROIVANT SCIENCES LTD - BREPOCITINIB PHASE 3 TRIAL IN NIU FULLY ENROLLED, DATA EXPECTED H2 2026</p></li><li><p>ROIVANT SCIENCES LTD - IMVT-1402 TRIAL IN D2T RA TOPLINE DATA EXPECTED 2026</p></li></ul><p>Source text: <span>ID:nGNX3LqfMN</span></p><p>Further company coverage: <span>ROIV.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day</title></head><body><p><span>Dec 11 (Reuters)</span><span> - </span>Roivant Sciences Ltd <span>ROIV.O</span>:</p><ul><li><p>ROIVANT HIGHLIGHTS CONTINUED PIPELINE PROGRESS AND OUTLOOK FOR COMPANY’S NEXT PHASE OF GROWTH AT 2025 INVESTOR DAY</p></li><li><p>ROIVANT SCIENCES LTD - BREPOCITINIB NDA FILING EXPECTED EARLY 2026, LAUNCH IN 2027</p></li><li><p>ROIVANT SCIENCES LTD - BREPOCITINIB PHASE 3 TRIAL IN NIU FULLY ENROLLED, DATA EXPECTED H2 2026</p></li><li><p>ROIVANT SCIENCES LTD - IMVT-1402 TRIAL IN D2T RA TOPLINE DATA EXPECTED 2026</p></li></ul><p>Source text: <span>ID:nGNX3LqfMN</span></p><p>Further company coverage: <span>ROIV.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA17ZN0Q:1","article_id":"2590513028","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590513028","pubTimestamp":1765456684,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor DayDec 11 (Reuters) - Roivant Sciences Ltd ROIV.O:ROIVANT HIGHLIGHTS CONTINUED PIPE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","ROIV":"Roivant Sciences Ltd."},"translate_title":"简介-Roivant在2025年投资者日强调了持续的管道进展以及公司下一阶段增长的前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":0.9},"content_text":"BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor DayDec 11 (Reuters) - Roivant Sciences Ltd ROIV.O:ROIVANT HIGHLIGHTS CONTINUED PIPELINE PROGRESS AND OUTLOOK FOR COMPANY’S NEXT PHASE OF GROWTH AT 2025 INVESTOR DAYROIVANT SCIENCES LTD - BREPOCITINIB NDA FILING EXPECTED EARLY 2026, LAUNCH IN 2027ROIVANT SCIENCES LTD - BREPOCITINIB PHASE 3 TRIAL IN NIU FULLY ENROLLED, DATA EXPECTED H2 2026ROIVANT SCIENCES LTD - IMVT-1402 TRIAL IN D2T RA TOPLINE DATA EXPECTED 2026Source text: ID:nGNX3LqfMNFurther company coverage: ROIV.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590513028","isCrawlerRequest":true}